0OB3.LSE Valneva SE
- Market cap
- EUR 212M
- P/E
- -
- P/B
- -
- ROE
- -156.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0OB3.LSE undervalued?
Graham numberThe Graham number of Valneva SE cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Valneva SE fundamental analysis
No fundamental analysis for Valneva SE yet.
Valneva SE stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, …
Full company profileValneva SE financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Valneva SE annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 94.1M | 105M | 113M | 126M | 110M | 348M | 361M | 154M | 170M | 175M | 132M |
| Gross Profit | 42.3M | 50.7M | 65.4M | 71.8M | 51.3M | 158M | 32.0M | -7.06M | 63.6M | 62.7M | 12.6M |
| Operating Income | -8.11M | -4.84M | 6.26M | -7.30M | -74.3M | -81.3M | -126M | -82.1M | -98.6M | -92.8M | -106M |
| EBITDA | -31.5M | 3.64M | 12.8M | 2.41M | -54.6M | -60.7M | -120M | -70.9M | 22.1M | -70.2M | -85.5M |
| Net Income | -49.2M | -11.5M | 3.26M | -1.74M | -64.4M | -73.4M | -143M | -101M | -12.2M | -115M | -127M |
| EPS | -0.66 | -0.15 | 0.04 | -0.02 | -0.71 | -0.75 | -1.24 | -0.73 | -0.08 | -0.68 | -0.67 |
| Balance Sheet | |||||||||||
| Total Assets | 207M | 189M | 240M | 274M | 460M | 826M | 633M | 469M | 510M | 399M | 388M |
| Total Liabilities | 107M | 96.7M | 96.6M | 139M | 382M | 655M | 413M | 341M | 329M | 293M | 307M |
| Shareholders' Equity | 100M | 92.7M | 143M | 135M | 77.4M | 171M | 220M | 128M | 181M | 106M | 81.1M |
| Cash & Short-term Investments | 42.2M | 38.1M | 81.7M | 64.4M | 204M | 347M | 289M | 126M | 168M | 110M | 122M |
| Total Debt | 82.5M | 71.5M | 57.6M | 85.2M | 108M | 115M | 152M | 209M | 219M | 207M | 210M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.14M | 7.92M | 12.3M | 3.11M | 133M | 68.5M | -254M | -203M | -84.8M | -81.8M | -45.0M |
| Capital Expenditure | 3.68M | 4.04M | 3.17M | 10.9M | 19.5M | 93.2M | 29.3M | 14.2M | 13.9M | 4.42M | 1.18M |
| Free Cash Flow | -4.82M | 3.88M | 9.15M | -7.78M | 114M | -24.6M | -284M | -217M | -98.7M | -86.2M | -46.2M |
| Ratios | |||||||||||
| ROE | -49.2% | -12.4% | 2.3% | -1.3% | -83.2% | -43.0% | -65.2% | -79.1% | -6.8% | -108.5% | -156.0% |
| ROA | -23.8% | -6.1% | 1.4% | -0.6% | -14.0% | -8.9% | -22.6% | -21.6% | -2.4% | -28.9% | -32.6% |
| Net Profit Margin | -52.3% | -10.9% | 2.9% | -1.4% | -58.4% | -21.1% | -39.7% | -66.0% | -7.2% | -66.0% | -96.1% |
| Debt to Equity | 0.82x | 0.77x | 0.40x | 0.63x | 1.40x | 0.67x | 0.69x | 1.63x | 1.21x | 1.95x | 2.59x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Valneva SE dividends
Valneva SE has not paid dividends in the last 9 fiscal years.
Who owns Valneva SE
- Insiders 10.69%
- Institutions 23.06%
- Public & others 66.25%
- Shares outstanding 76.5M
- Free float 171M
Valneva SE company profile
- Company name
- Valneva SE
- Ticker
- 0OB3.LSE
- ISIN
- FR0004056851
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 620
- Fiscal year end
- December
- Address
- 6 rue Alain Bombard, Saint-Herblain, France, 44800
- Phone
- 33 2 28 07 37 10
- Website
- valneva.com
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
Valneva SE management
10- Mr. Thomas LingelbachPresident, CEO & Director · born 1963
- Mr. Peter BuhlerChief Financial Officer · born 1971
- Dr. Juan-Carlos Jaramillo M.D.Chief Medical Officer · born 1972
- Ms. Dipal PatelChief Commercial Officer · born 1975
- Mr. Vincent DequenneChief Operating Officer · born 1967
- Dr. Hanneke Schuitemaker Ph.D.Chief Scientific Officer · born 1965
- Mr. Joshua Drumm Ph.D.Vice President of Investor Relations
- Ms. Laetitia Bachelot-FontaineVP of Global Communications & European Investor Relations
- Ms. Petra PesendorferChief People Officer · born 1986
- Katrin DubischarVP & Program Director of Chikungunya Vaccine